233 related articles for article (PubMed ID: 22711415)
1. Washout gradient in dynamic contrast-enhanced MRI is associated with tumor aggressiveness of prostate cancer.
Chen YJ; Chu WC; Pu YS; Chueh SC; Shun CT; Tseng WY
J Magn Reson Imaging; 2012 Oct; 36(4):912-9. PubMed ID: 22711415
[TBL] [Abstract][Full Text] [Related]
2. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis.
Oto A; Yang C; Kayhan A; Tretiakova M; Antic T; Schmid-Tannwald C; Eggener S; Karczmar GS; Stadler WM
AJR Am J Roentgenol; 2011 Dec; 197(6):1382-90. PubMed ID: 22109293
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer detection on dynamic contrast-enhanced MRI: computer-aided diagnosis versus single perfusion parameter maps.
Sung YS; Kwon HJ; Park BW; Cho G; Lee CK; Cho KS; Kim JK
AJR Am J Roentgenol; 2011 Nov; 197(5):1122-9. PubMed ID: 22021504
[TBL] [Abstract][Full Text] [Related]
4. Detection of prostate cancer in peripheral zone: comparison of MR diffusion tensor imaging, quantitative dynamic contrast-enhanced MRI, and the two techniques combined at 3.0 T.
Li C; Chen M; Li S; Zhao X; Zhang C; Luo X; Zhou C
Acta Radiol; 2014 Mar; 55(2):239-47. PubMed ID: 23892233
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer: comparison of dynamic contrast-enhanced MRI techniques for localization of peripheral zone tumor.
Rosenkrantz AB; Sabach A; Babb JS; Matza BW; Taneja SS; Deng FM
AJR Am J Roentgenol; 2013 Sep; 201(3):W471-8. PubMed ID: 23971479
[TBL] [Abstract][Full Text] [Related]
6. Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology.
Selnæs KM; Heerschap A; Jensen LR; Tessem MB; Schweder GJ; Goa PE; Viset T; Angelsen A; Gribbestad IS
Invest Radiol; 2012 Nov; 47(11):624-33. PubMed ID: 23011187
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
[TBL] [Abstract][Full Text] [Related]
8. MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters.
Riches SF; Payne GS; Morgan VA; Sandhu S; Fisher C; Germuska M; Collins DJ; Thompson A; deSouza NM
AJR Am J Roentgenol; 2009 Dec; 193(6):1583-91. PubMed ID: 19933651
[TBL] [Abstract][Full Text] [Related]
9. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging.
Kitajima K; Kaji Y; Fukabori Y; Yoshida K; Suganuma N; Sugimura K
J Magn Reson Imaging; 2010 Mar; 31(3):625-31. PubMed ID: 20187206
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast enhanced MRI of the prostate: comparison of gadobutrol and Gd-DTPA.
Durmus T; Vollnberg B; Schwenke C; Kilic E; Huppertz A; Taupitz M; Franiel T
Rofo; 2013 Sep; 185(9):862-8. PubMed ID: 23888476
[TBL] [Abstract][Full Text] [Related]
12. Reproducibility of the aortic input function (AIF) derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the kidneys in a volunteer study.
Mendichovszky IA; Cutajar M; Gordon I
Eur J Radiol; 2009 Sep; 71(3):576-81. PubMed ID: 19004588
[TBL] [Abstract][Full Text] [Related]
13. Solid pancreatic lesions: characterization by using timing bolus dynamic contrast-enhanced MR imaging assessment--a preliminary study.
Kim JH; Lee JM; Park JH; Kim SC; Joo I; Han JK; Choi BI
Radiology; 2013 Jan; 266(1):185-96. PubMed ID: 23192779
[TBL] [Abstract][Full Text] [Related]
14. Enhanced mass on contrast-enhanced breast MR imaging: Lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images.
Yabuuchi H; Matsuo Y; Okafuji T; Kamitani T; Soeda H; Setoguchi T; Sakai S; Hatakenaka M; Kubo M; Sadanaga N; Yamamoto H; Honda H
J Magn Reson Imaging; 2008 Nov; 28(5):1157-65. PubMed ID: 18972357
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of semi-quantitative dynamic contrast-enhanced MRI parameters for prostate cancer in correlation to whole-mount histopathology.
Isebaert S; De Keyzer F; Haustermans K; Lerut E; Roskams T; Roebben I; Van Poppel H; Joniau S; Oyen R
Eur J Radiol; 2012 Mar; 81(3):e217-22. PubMed ID: 21349667
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence.
Franiel T; Lüdemann L; Rudolph B; Rehbein H; Staack A; Taupitz M; Prochnow D; Beyersdorff D
Invest Radiol; 2008 Jul; 43(7):481-7. PubMed ID: 18580330
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of dynamic contrast enhanced MRI for assessment of bowel inflammation in Crohn's disease pilot study.
Oto A; Fan X; Mustafi D; Jansen SA; Karczmar GS; Rubin DT; Kayhan A
Acad Radiol; 2009 Oct; 16(10):1223-30. PubMed ID: 19524458
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive estimation of prostate cancer aggressiveness using diffusion-weighted MRI and 3D proton MR spectroscopy at 3.0 T.
Thörmer G; Otto J; Horn LC; Garnov N; Do M; Franz T; Stolzenburg JU; Moche M; Kahn T; Busse H
Acta Radiol; 2015 Jan; 56(1):121-8. PubMed ID: 24504488
[TBL] [Abstract][Full Text] [Related]
19. [Quantitative dynamic MRI and localisation of non-palpable prostate cancer].
Cornud F; Beuvon F; Thévenin F; Chauveinc L; Vieillefond A; Descazeaux A; Flam T
Prog Urol; 2009 Jun; 19(6):401-13. PubMed ID: 19467459
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer?
Itou Y; Nakanishi K; Narumi Y; Nishizawa Y; Tsukuma H
J Magn Reson Imaging; 2011 Jan; 33(1):167-72. PubMed ID: 21182135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
